Phaseline

Companies › Puma Biotechnology

Puma Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Alisertib
Serine/threonine-protein kinase Aurora-A inhibitor
AURKAPhase 2Small Cell Lung Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Small Cell Lung Cancer ( SCLC ); Malignant Rhabdoid Tumor …Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01695941AlisertibPhase 1Recurrent B-Cell Non-Hodgkin LymphomaOncologyMar 2027
NCT02114229AlisertibPhase 2Malignant Rhabdoid TumorOncologySep 2027
NCT06095505AlisertibPhase 2Small Cell Lung CancerOncologyOct 2027
NCT06369285AlisertibPhase 2Hormone Receptor Positive HER-2 Negative Breast CancerOncologyDec 2027
NCT07465757AlisertibPhase 2Small Cell Lung Cancer ( SCLC )OncologyMar 2028

From the company's SEC filings

Cash and short-term investments of $101m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

AURKA (1)

Companies with the same targets

Jacobio Pharmaceuticals

Companies built like this

C4 Therapeutics Compass Therapeutics Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.